Inhibitory effects of TTP sera on binding of anti‐platelet glycoprotein II b ‐III a  monoclonal antibodies to human vascular endothelial cells | Zendy

Nakajima Tokuo | Zendy; Koyama Tetsuji | Zendy; Kakishita Eizo | Zendy; Nagai Kiyoyasu | Zendy

Premium

Inhibitory effects of TTP sera on binding of anti‐platelet glycoprotein II b ‐III a monoclonal antibodies to human vascular endothelial cells

Author(s) -

Nakajima Tokuo,

Koyama Tetsuji,

Kakishita Eizo,

Nagai Kiyoyasu

Publication year - 1987

Publication title -

american journal of hematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.456

H-Index - 105

eISSN - 1096-8652

pISSN - 0361-8609

DOI - 10.1002/ajh.2830250113

Subject(s) - monoclonal antibody , platelet , umbilical vein , glycoprotein , antibody , microbiology and biotechnology , monoclonal , chemistry , endothelial stem cell , platelet membrane glycoprotein , immunology , medicine , biochemistry , biology , in vitro

The binding of anti‐human platelet glycoprotein (GP) II b III a monoclonal antibodies to human umbilical vein endothelial cells (HUVE) was studied. Scatchard analysis using 125 I‐anti‐platelet GPII b ‐III a monoclonal antibody showed that the maximum binding capacity (B max) was 8 × 10 4 /cell and Kd was 40.2 nM. The binding rate of 125 I‐anti‐platelet GPII b III a monoclonal antibodies to HUVE treated with TTP sera was 11.6 ± 2.8%, compared with the 24.0 ± 7.5% observed for HUVE treated with normal sera. These findings showed that there are GPII b ‐III a on HUVE and that TTP sera may contain anti‐platelet GPII b III a antibodies.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research